Please use this identifier to cite or link to this item:
Title: Cord blood and amniotic membrane extract eye drop preparations display immune-suppressive and regenerative properties
Author: Samarkanova, Dinara
Cox, Steven
Hernández, Diana
Rodriguez Gómez, Luciano
Pérez, Maria Luisa
Madrigal, Alejandro
Vilarrodona, Anna
Querol Giner, Sergi
Casaroli Marano, Ricardo Pedro
Keywords: Immunologia de la trasplantació
Transplantation immunology
Issue Date: 2-Jul-2021
Publisher: Nature Publishing Group
Abstract: long term consequences for their quality of life. Treatment modalities that can address the delicate balance of tissue regeneration, inflammation and maintenance of corneal transparency are therefore needed. We have recently formulated two novel eye drops from placental tissues: cord blood platelet lysate (CBED) and amniotic membrane extract eye drops (AMED), which can be used to treat severe ocular disorders. Here we characterise these two preparations by measuring: (a) growth factors (GF) and cytokines composition, (b) promotion of human corneal epithelial cell (HCEC) growth and (c) effects on immune cells in a lymphocyte culture assay. Finally, their bioavailability was assayed in an ex vivo porcine corneal model. We show that both preparations contain GF and cytokines that were able to promote the in vitro growth of HCEC and support repair in an in vitro scratch test. When assessed in a lymphocyte culture, both favoured immune suppression reducing the cellular expression of NKG2D and CD107a as well as the production of interferon gamma (IFN-γ) in natural killer, NKT and T cells. Regarding bioavailability, CBED active molecules were found mainly in the pre-corneal fraction with some penetration into the corneal fraction, in an ex vivo model. In summary, both placentalderived allogeneic preparations, CBED and AMED, display regenerative and immunomodulatory capabilities. These results will help define mechanisms of action and the best indications and doses of each product for use in a particular patient and support the development of off-the-shelf therapies for ocular surface pathologies in which wound healing defects and inflammatory events are contributing factors.
Note: Reproducció del document publicat a:
It is part of: Scientific Reports, 2021, vol. 11, num. 1, p. 13754
Related resource:
ISSN: 2045-2322
Appears in Collections:Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)

Files in This Item:
File Description SizeFormat 
720278.pdf1.41 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons